Find Candesartan Cilexetil manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 145040-37-5, Atacand, Tcv-116, Amias, Parapres, Kenzen
Molecular Formula
C33H34N6O6
Molecular Weight
610.7  g/mol
InChI Key
GHOSNRCGJFBJIB-UHFFFAOYSA-N
FDA UNII
R85M2X0D68

Candesartan Cilexetil
Candesartan Cilexetil is a synthetic, benzimidazole-derived angiotensin II receptor antagonist prodrug with antihypertensive activity. After hydrolysis of candesartan cilexetil to candesartan during gastrointestinal absorption, candesartan selectively competes with angiotensin II for the binding of the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation. In addition, antagonism of AT1 in the adrenal gland inhibits angiotensin II-stimulated aldosterone synthesis and secretion by the adrenal cortex; sodium and water excretion increase, followed by a reduction in plasma volume and blood pressure.
1 2D Structure

Candesartan Cilexetil

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
2.1.2 InChI
InChI=1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)
2.1.3 InChI Key
GHOSNRCGJFBJIB-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC6
2.2 Other Identifiers
2.2.1 UNII
R85M2X0D68
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1h-tetrazol-5-yl)biphenyl-4-yl)-1h-benzimidazole-7-carboxylate

2. 1h-benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, Hydroxide, Inner Salt, (+-)-

3. Amias

4. Atacand

5. Blopress

6. Kenzen

7. Parapres

8. Tcv 116

9. Tcv-116

2.3.2 Depositor-Supplied Synonyms

1. 145040-37-5

2. Atacand

3. Tcv-116

4. Amias

5. Parapres

6. Kenzen

7. Candesartan Cilextil

8. Tcv 116

9. Candesartancilexetil

10. Candesartan Cilexetil [usan]

11. Nsc-758697

12. Chembl1014

13. Chebi:3348

14. 1-(((cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylate

15. R85m2x0d68

16. 1-(cyclohexyloxycarbonyloxy)ethyl 1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylate

17. 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate

18. 1-(((cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylate

19. Candesartan 1-(((cyclohexyloxy)carbonyl)oxy)ethyl Ester

20. Candesartan 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl Ester

21. Racanda

22. Unii-r85m2x0d68

23. Tcy 116

24. Candesartan Hexetil

25. 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate

26. Atacand (tn)

27. Candesartan Cilexitil

28. Mfcd00871371

29. Spectrum_001707

30. Candesartan (cilexetil)

31. Dsstox_cid_239

32. Spectrum2_000485

33. Spectrum3_000996

34. Spectrum4_001124

35. Spectrum5_001462

36. Candesartan Celexetil Ester

37. Dsstox_rid_85567

38. Dsstox_gsid_20239

39. Schembl40831

40. Bspbio_002691

41. Candesartan Cilexetil- Bio-x

42. Kbiogr_001607

43. Kbioss_002187

44. 1h-benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, Hydroxide, Inner Salt, (+-)-

45. Candesartan Cilexetil-[d11]

46. Mls004774127

47. Candesartan Cilexetil , 97%

48. Spectrum1504261

49. Spbio_000349

50. Gtpl8352

51. Candesartan Cilexetil (atacand)

52. Dtxsid5020239

53. Kbio2_002187

54. Kbio2_004755

55. Kbio2_007323

56. Kbio3_001911

57. Hms1922j09

58. Hms2093e20

59. Hms3651i08

60. Pharmakon1600-01504261

61. Candesartan Cilexetil (jp17/usp)

62. Candesartan Cilexetil [jan]

63. Bcp22050

64. Tox21_302202

65. Ac-204

66. Bdbm50318907

67. Candesartan Cilexetil [vandf]

68. Ccg-39530

69. Nsc758697

70. S2037

71. Stl451065

72. Candesartan Cilexetil [mart.]

73. Akos015894954

74. Akos015920180

75. Candesartan Cilexetil [usp-rs]

76. Candesartan Cilexetil [who-dd]

77. Ab07617

78. Am90293

79. Bcp9000480

80. Ccg-222334

81. Db00796

82. Ds-1302

83. Ks-1147

84. Nsc 758697

85. Candesartan Cilexetil, >=98% (hplc)

86. Ncgc00095123-01

87. Ncgc00095123-02

88. Ncgc00095123-03

89. Ncgc00095123-05

90. Ncgc00095123-10

91. Ncgc00095123-16

92. Ncgc00255218-01

93. (+-)-1-hydroxyethyl 2-ethoxy-1-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, Cyclohexyl Carbonate (ester)

94. 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl 2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylate

95. 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-(ethyloxy)-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylate

96. 1h-benzimidazole-7-carboxylic Acid, 2-ethoxy-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl Ester, (+-)-

97. 2-ethoxy-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylic Acid 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl Ester

98. 2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic Acid 1-cyclohexyloxycarbonyloxy-ethyl Ester

99. Bc164274

100. Hy-17505

101. Smr003500784

102. Candesartan Cilexetil [orange Book]

103. Sbi-0206767.p001

104. Candesartan Cilexetil [ep Monograph]

105. Candesartan Cilexetil [usp Monograph]

106. Cas-145040-37-5

107. Ft-0602914

108. Sw220041-1

109. C07709

110. D00626

111. Ab01274805-01

112. Ab01274805_02

113. Ab01274805_03

114. 040c375

115. H212/91

116. L006257

117. Sr-05000001976

118. Camptothecine, Antibiotic For Culture Media Use Only

119. Q-200786

120. Sr-05000001976-1

121. Brd-a65671304-001-02-6

122. Brd-a65671304-001-03-4

123. Q27075664

124. Candesartan 1-(((cyclohexyloxy)carbonyl)oxy)ethyl Ester [mi]

125. Candesartan Cilexetil, European Pharmacopoeia (ep) Reference Standard

126. Candesartan Cilexetil, United States Pharmacopeia (usp) Reference Standard

127. Candesartan Cilexetil For Peak Identification, European Pharmacopoeia (ep) Reference Standard

128. Candesartan Cilexetil For System Suitability, European Pharmacopoeia (ep) Reference Standard

129. Candesartan Cilexetil, Pharmaceutical Secondary Standard; Certified Reference Material

130. (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[2'-(1h-tetrazol-5-yl) Biphenyl-4-yl]methylbenzimidazole-7-carboxylate

131. (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methylbenzimidazole-7-carboxylate

132. (+/-)1-hydroxyethyl 2-ethoxy-1-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, Cyclohexyl Carbonate (ester)

133. 1-(((cyclohexyloxy)carbonyl)oxy)ethyl1-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1h-benzo[d]imidazole-7-carboxylate

134. 1-(cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazol-7-carboxylate

135. 1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylate

136. 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl] Methyl]benzimidazole-4-carboxylate

137. 1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate.

138. 1h-benzimidazole-7-carboxylic Acid, 2-ethoxy-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl Ester, (+/-)-

139. 1h-benzimidazole-7-carboxylic Acid, 2-ethoxy-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl Ester

140. 2-ethoxy-1-[2'-(1h-tetrazole-5-yl)-4-biphenylylmethyl]-1h-benzimidazole-7-carboxylic Acid 1-(cyclohexyloxycarbonyloxy)ethyl Ester

141. 2-ethoxy-3-[2''-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic Acid 1-cyclohexyloxycarbonyloxy-ethyl Ester

142. 2-ethoxy-3-[2''-(2h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic Acid 1-cyclohexyloxycarbonyloxy-ethyl Ester

143. 2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic Acid 1-cyclohe

2.3.3 Other Synonyms

1. Candesartan

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 610.7 g/mol
Molecular Formula C33H34N6O6
XLogP37
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count10
Rotatable Bond Count13
Exact Mass610.25398283 g/mol
Monoisotopic Mass610.25398283 g/mol
Topological Polar Surface Area143 Ų
Heavy Atom Count45
Formal Charge0
Complexity962
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 6  
Drug NameAtacand
PubMed HealthCandesartan (By mouth)
Drug ClassesAngiotensin II Receptor Antagonist/Thiazide Combination
Drug LabelATACAND (candesartan cilexetil), a prodrug, is hydrolyzed to candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin II receptor antagonist.Candesartan cilexetil, a nonpeptide, is chemically d...
Active IngredientCandesartan cilexetil
Dosage FormTablet
RouteOral
Strength32mg; 4mg; 16mg; 8mg
Market StatusPrescription
CompanyAstrazeneca

2 of 6  
Drug NameAtacand hct
PubMed HealthCandesartan/Hydrochlorothiazide (By mouth)
Active Ingredienthydrochlorothiazide; Candesartan cilexetil
Dosage FormTablet
RouteOral
Strength32mg; 25mg; 16mg; 12.5mg
Market StatusPrescription
CompanyAstrazeneca

3 of 6  
Drug NameCandesartan cilexetil
Drug LabelCandesartan cilexetil, a prodrug, is hydrolyzed to candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin II receptor antagonist.Candesartan cilexetil, a nonpeptide, is chemically described a...
Active IngredientCandesartan cilexetil
Dosage FormTablet
Routeoral; Oral
Strength32mg; 4mg; 16mg; 8mg
Market StatusTentative Approval; Prescription
CompanyMatrix Labs; Apotex; Sandoz

4 of 6  
Drug NameAtacand
PubMed HealthCandesartan (By mouth)
Drug ClassesAngiotensin II Receptor Antagonist/Thiazide Combination
Drug LabelATACAND (candesartan cilexetil), a prodrug, is hydrolyzed to candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin II receptor antagonist.Candesartan cilexetil, a nonpeptide, is chemically d...
Active IngredientCandesartan cilexetil
Dosage FormTablet
RouteOral
Strength32mg; 4mg; 16mg; 8mg
Market StatusPrescription
CompanyAstrazeneca

5 of 6  
Drug NameAtacand hct
PubMed HealthCandesartan/Hydrochlorothiazide (By mouth)
Active Ingredienthydrochlorothiazide; Candesartan cilexetil
Dosage FormTablet
RouteOral
Strength32mg; 25mg; 16mg; 12.5mg
Market StatusPrescription
CompanyAstrazeneca

6 of 6  
Drug NameCandesartan cilexetil
Drug LabelCandesartan cilexetil, a prodrug, is hydrolyzed to candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin II receptor antagonist.Candesartan cilexetil, a nonpeptide, is chemically described a...
Active IngredientCandesartan cilexetil
Dosage FormTablet
Routeoral; Oral
Strength32mg; 4mg; 16mg; 8mg
Market StatusTentative Approval; Prescription
CompanyMatrix Labs; Apotex; Sandoz

4.2 Drug Indication

May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.


FDA Label


Diabetic retinopathy, Essential hypertension, Heart Failure


Diabetic retinopathy, Essential hypertension, Heart Failure


5 Pharmacology and Biochemistry
5.1 Pharmacology

Candesartan cilexetil is an ARB prodrug that is rapidly converted to candesartan, its active metabolite, during absorption from the gastrointestinal tract. Candesartan confers blood pressure lowering effects by antagonizing the hypertensive effects of angiotensin II via the RAAS. RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: type-1 angiotensin II receptor (AT1) and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.


5.2 MeSH Pharmacological Classification

Antihypertensive Agents

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)


Angiotensin II Type 1 Receptor Blockers

Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS. (See all compounds classified as Angiotensin II Type 1 Receptor Blockers.)


5.3 FDA Pharmacological Classification
5.3.1 Pharmacological Classes
Angiotensin 2 Receptor Blocker [EPC]; Angiotensin 2 Receptor Antagonists [MoA]
5.4 Absorption, Distribution and Excretion

Absorption

Following administration of the candesartan cilexetil prodrug, the absolute bioavailability of candesartan was estimated to be 15%. Food with a high fat content has no effect on the bioavailability of candesartan from candesartan cilexetil.


Route of Elimination

When candesartan is administered orally, about 26% of the dose is excreted unchanged in urine. Candesartan is mainly excreted unchanged in urine and feces (via bile).


Volume of Distribution

0.13 L/kg


Clearance

0.37 mL/min/kg


5.5 Metabolism/Metabolites

The prodrug candesartan cilexetil undergoes rapid and complete ester hydrolysis in the intestinal wall to form the active drug, candesartan. Elimination of candesartan is primarily as unchanged drug in the urine and, by the biliary route, in the feces. Minor hepatic metabolism of candesartan (<20%) occurs by O-deethylation via cytochrome P450 2C9 to form an inactive metabolite. Candesartan undergoes N-glucuronidation in the tetrazole ring by uridine diphosphate glucuronosyltransferase 1A3 (UGT1A3). O-glucuronidation may also occur. 75% of candesartan is excreted as unchanged drug in urine and feces.


5.6 Biological Half-Life

Approximately 9 hours.


5.7 Mechanism of Action

Candesartan selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Candesartan is greater than 10,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion.


API SUPPLIERS

read-more
read-more

01

Octavius Pharma Pvt. Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOctavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Octavius Pharma

02

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LGM Pharma CB

03

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Metrochem

04

Jai Radhe Sales

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJai Radhe Sales is your partner for all your sourcing needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Jai Radhe Sales

05

ULKAR KIMYA SANAYII VE TICARET

Turkey

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

ULKAR KIMYA SANAYII VE TICARET

Turkey

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

ULKAR KIMYA SANAYII VE TICARET

Turkey

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

ULKAR KIMYA SANAYII VE TICARET

Turkey

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Zhejiang Huahai Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Zhejiang Huahai Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF arrow-down EU-WC NDC arrow-down KDMF arrow-down VMF Others AUDIT arrow-down
blank

08

Torrent Pharmaceuticals Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Torrent Pharmaceuticals Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

09

Zhuhai Rundu Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Zhuhai Rundu Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF arrow-down EU-WC NDC KDMF arrow-down VMF Others AUDIT arrow-down
blank

10

Lek Pharmaceuticals

Slovenia

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Lek Pharmaceuticals

Slovenia

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF Inactive-api CEP/COS JDMF arrow-down EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

PEGS Boston Summit
Not Confirmed

01

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 21507

Submission : 2008-03-31

Status : Inactive

Type : II

blank

02

Astra Merck Inc

United Kingdom

USDMF

arrow
PEGS Boston Summit
Not Confirmed

02

Astra Merck Inc

United Kingdom
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 11487

Submission : 1995-05-01

Status : Inactive

Type : II

blank

03

PEGS Boston Summit
Not Confirmed

03

04

Jubilant Pharmova Ltd

India

USDMF

arrow
PEGS Boston Summit
Not Confirmed

04

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 21374

Submission : 2008-05-21

Status : Inactive

Type : II

blank

05

Lek Pharmaceuticals Dd

Slovenia

USDMF

arrow
PEGS Boston Summit
Not Confirmed

05

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 20053

Submission : 2006-12-18

Status : Inactive

Type : II

blank

06

PEGS Boston Summit
Not Confirmed

07

PEGS Boston Summit
Not Confirmed

07

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 22672

Submission : 2009-03-30

Status : Active

Type : II

blank

08

PEGS Boston Summit
Not Confirmed

08

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 20400

Submission : 2007-04-02

Status : Active

Type : II

blank

09

PEGS Boston Summit
Not Confirmed

09

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 18828

Submission : 2005-10-03

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOctavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.

Flag India
Digital Content Digital Content

Candesartan Cilexetil

About the Company : Octavius Pharma is a global leader in Directly Compressible Granules with over 45 years of experience in formulation development, manufacturing, and commercialization. Its portfoli...

Octavius Pharma is a global leader in Directly Compressible Granules with over 45 years of experience in formulation development, manufacturing, and commercialization. Its portfolio includes DC granules, herbal and food supplements, APIs, and finished formulations such as tablets, capsules, syrups, and ointments. With WHO-GMP certification and a DSIR-certified R&D center, the company ensures quality and innovation, exporting to LATAM, the Middle East, Africa, Asia, and CIS regions, and offering formulation and marketing support. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Octavius Pharma

02

LGM Pharma

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content

Candesartan Cilexetil

About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...

LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product CDMO, offering formulation, analytical method development and testing, regulatory support, and commercial manufacturing. Supported by a network of over 220 accredited cGMP manufacturing partners and more than 100,000 sq. ft. of FDA-inspected cGMP manufacturing and warehouse space, LGM delivers secure, end-to-end solutions across multiple dosage forms. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
LGM Pharma CB

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Candesartan

About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJai Radhe Sales is your partner for all your sourcing needs.

Flag India
Digital Content Digital Content

Candesartan Cilexetil

About the Company : Jai Radhe Sales, founded in 1999, is a global distributor specializing in high-quality pharmaceutical ingredients from India. It offers complete sourcing solutions, technical and r...

Jai Radhe Sales, founded in 1999, is a global distributor specializing in high-quality pharmaceutical ingredients from India. It offers complete sourcing solutions, technical and regulatory support, and strives for global standards. Known for quality and affordability, it has established a niche through innovative methods and exports to nearly every continent. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Jai Radhe Sales

05

Acura Labs

India
PEGS Boston Summit
Not Confirmed
arrow

Acura Labs

India
arrow
PEGS Boston Summit
Not Confirmed

Candesartan Cilexetil

About the Company : Acura Labs is one of the fastest-growing pharmaceutical companies backed by a solid and innovative R&D facility and a top-notch Active Pharmaceutical Ingredients (APIs) manufacturi...

Acura Labs is one of the fastest-growing pharmaceutical companies backed by a solid and innovative R&D facility and a top-notch Active Pharmaceutical Ingredients (APIs) manufacturing facility. We have a robust product portfolio of APIs spread across various therapeutic areas, capable of handling novel, complex and critical reactions. We are equipped with adaptable, versatile, and cutting-edge infrastructure tailored to fit any complex chemistry molecules and satisfy the needs of global innovators.
blank

06

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Candesartan Cilexetil

About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...

Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates.
blank

07

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Candesartan Cilexetil

About the Company : Asia Pioneer Pharmaceuticals is a leading supplier of fine chemicals, pharmaceutical intermediates, active pharmaceutical ingredients and other compounds. It also offers finished p...

Asia Pioneer Pharmaceuticals is a leading supplier of fine chemicals, pharmaceutical intermediates, active pharmaceutical ingredients and other compounds. It also offers finished product licensing, custom manufacturing and outsourcing services. In partnership with state-of-the-art manufacturers in China, Asia Pioneer provides world-class quality products at excellent value, in full compliance with standards required by leading regulatory agencies in the USA and Europe.
blank

08

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Candesartan Cilexetil

About the Company : Smilax Laboratories Limited is a research-driven, vertically integrated pharmaceutical company manufacturing Active Pharmaceutical Ingredients, API Intermediates and NDDS/Pellets f...

Smilax Laboratories Limited is a research-driven, vertically integrated pharmaceutical company manufacturing Active Pharmaceutical Ingredients, API Intermediates and NDDS/Pellets for the generics market across the world. Set up in 2005, Smilax has emerged a reliable supplier of generic products in the global market today. Set up in 2005, Smilax has emerged a reliable supplier of generic products in the global market today.Set up in 2005, Smilax has emerged a reliable supplier of generic products in the global market today. Smilax manufactures APIs and API Intermediates at its state-of-the-art manufacturing facilities located at Hyderabad, Telangana and Visakhapatnam, Andhra Pradesh, India. Supported by a highly qualified and competent technical team, and endowed with strengths in research and development, Smilax continues to expand its presence in the world of pharmaceuticals.
blank

09

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

Candesartan Cilexetil

About the Company : Titan Laboratories is leading EU GMP approved Site for Sustained and Modified Release Pellets, Direct Compressible Granules, Tablets & Capsules.Our major focus in EU market is for1...

Titan Laboratories is leading EU GMP approved Site for Sustained and Modified Release Pellets, Direct Compressible Granules, Tablets & Capsules.Our major focus in EU market is for1) CONTRACT MANUFACTURING SERVICES:-> As approved Dossier Manufacturer.-> Site variation basis.-> cGMP pilot batch for BE/BA or Clinical Studies.2) CONTRACT RESEARCH SERVICES:-> Product Development - Generic Equivalent, Novel Sustained & Combination Products-> Method Development & Validation-> Dossier Preparation-> Stability Studies
blank

10

Unipex

France
PEGS Boston Summit
Not Confirmed
arrow

Unipex

France
arrow
PEGS Boston Summit
Not Confirmed

HMS3715F13

About the Company : Our work in the distribution sector starts and ends with the quality of human relations; first and foremost, it is trust that we want to build with you. The connections we build ar...

Our work in the distribution sector starts and ends with the quality of human relations; first and foremost, it is trust that we want to build with you. The connections we build are made to last. They are built on professionalism, respect and transparency. This is how we work, and how we have been working for a long time now, with our client partners and constituents. Unipex has been operational for 50 years, and has always remained true to its core business: the distribution of specialities. This is also why we are independent and we intend to stay that way. Our structure is simple, our commitment is absolute: we work directly with you.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATE SUPPLIERS

read-more
read-more

01

Almelo

India
PEGS Boston Summit
Not Confirmed
arrow

Almelo

India
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : CAS-139481-44-0

End Use API : Candesartan Cilexetil

About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...

blank

02

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 170791-09-0

End Use API : Candesartan Cilexetil

About The Company : Jiangsu Zhongbang Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Red Sun Group. Company has been founded since 2001 and occupied 100,000m2. Company ha...

blank

03

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 114772-54-2

End Use API : Candesartan Cilexetil

About The Company : Louis Pharmaceuticals Private Limited is an Advanced Intermediates Manufacturing firm. The Company is established in 2009 and has an integrated focus from vario...

blank

04

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 99464-83-2

End Use API : Candesartan Cilexetil

About The Company : LUNA Chemicals Co.,Ltd. markets and manufactures world-class quality Active Pharmaceutical Ingredients and intermediate chemicals for generic pharmaceutical com...

blank

05

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 139481-44-0

End Use API : Candesartan Cilexetil

About The Company : Medilux Laboratories has been providing quality back-end support to the pharmaceutical industry since our inception in 1988. Our resources are dedicated to prom...

blank

06

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 76-83-5

End Use API : Candesartan Cilexetil

About The Company : Riddhi Pharma was set up in 1997 as a Manufacturer of API’s Intermediates and Fine Chemicals, especially in the field of Friedel Crafts Reaction / Bromination...

blank

07

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 78-09-1

End Use API : Candesartan Cilexetil

About The Company : SAINTSUN PHARMA, we are engaging mainly in the manufacturing and distributing APIs, Pharmaceutical Intermediates, Chemicals, Formulations, Medical supplies, etc...

blank

08

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 76-83-5

End Use API : Candesartan Cilexetil

About The Company : Shree Ganesh Remedies is established Since 1995 with an aim to manufacture, supply and export best quality of Pharmaceutical-intermediates, Bulk drugs and Speci...

blank

09

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 124750-51-2

End Use API : Candesartan Cilexetil

About The Company : Smilax Laboratories Limited is a research-driven, vertically integrated pharmaceutical company manufacturing Active Pharmaceutical Ingredients, API Intermediate...

blank

10

PEGS Boston Summit
Not Confirmed
arrow
PEGS Boston Summit
Not Confirmed
arrow

CAS Number : 139481-59-7

End Use API : Candesartan Cilexetil

About The Company : Smilax Laboratories Limited is a research-driven, vertically integrated pharmaceutical company manufacturing Active Pharmaceutical Ingredients, API Intermediate...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - TABLET;ORAL - 16MG

USFDA APPLICATION NUMBER - 20838

read-more

DOSAGE - TABLET;ORAL - 32MG

USFDA APPLICATION NUMBER - 20838

read-more

DOSAGE - TABLET;ORAL - 4MG

USFDA APPLICATION NUMBER - 20838

read-more

DOSAGE - TABLET;ORAL - 8MG

USFDA APPLICATION NUMBER - 20838

read-more

DOSAGE - TABLET;ORAL - 16MG;12.5MG

USFDA APPLICATION NUMBER - 21093

read-more

DOSAGE - TABLET;ORAL - 32MG;12.5MG

USFDA APPLICATION NUMBER - 21093

read-more

DOSAGE - TABLET;ORAL - 32MG;25MG

USFDA APPLICATION NUMBER - 21093

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Topical

read-more
read-more

Granulation

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Taste Masking

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Parenteral

read-more
read-more

Lubricants & Glidants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Solubilizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Coating Systems & Additives

read-more
read-more

Emulsifying Agents

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ANALYTICAL

Upload your methods for free, ask us

Analytical Methods

read-more
read-more

ABOUT THIS PAGE

Looking for 145040-37-5 / Candesartan Cilexetil API manufacturers, exporters & distributors?

Candesartan Cilexetil manufacturers, exporters & distributors 1

47

PharmaCompass offers a list of Candesartan Cilexetil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Candesartan Cilexetil manufacturer or Candesartan Cilexetil supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Candesartan Cilexetil manufacturer or Candesartan Cilexetil supplier.

API | Excipient name

Candesartan Cilexetil

Synonyms

145040-37-5, Atacand, Tcv-116, Amias, Parapres, Kenzen

Cas Number

145040-37-5

Unique Ingredient Identifier (UNII)

R85M2X0D68

About Candesartan Cilexetil

Candesartan Cilexetil is a synthetic, benzimidazole-derived angiotensin II receptor antagonist prodrug with antihypertensive activity. After hydrolysis of candesartan cilexetil to candesartan during gastrointestinal absorption, candesartan selectively competes with angiotensin II for the binding of the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation. In addition, antagonism of AT1 in the adrenal gland inhibits angiotensin II-stimulated aldosterone synthesis and secretion by the adrenal cortex; sodium and water excretion increase, followed by a reduction in plasma volume and blood pressure.

Blopress Manufacturers

A Blopress manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Blopress, including repackagers and relabelers. The FDA regulates Blopress manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Blopress API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Blopress manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Blopress Suppliers

A Blopress supplier is an individual or a company that provides Blopress active pharmaceutical ingredient (API) or Blopress finished formulations upon request. The Blopress suppliers may include Blopress API manufacturers, exporters, distributors and traders.

click here to find a list of Blopress suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Blopress USDMF

A Blopress DMF (Drug Master File) is a document detailing the whole manufacturing process of Blopress active pharmaceutical ingredient (API) in detail. Different forms of Blopress DMFs exist exist since differing nations have different regulations, such as Blopress USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Blopress DMF submitted to regulatory agencies in the US is known as a USDMF. Blopress USDMF includes data on Blopress's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Blopress USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Blopress suppliers with USDMF on PharmaCompass.

Blopress JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Blopress Drug Master File in Japan (Blopress JDMF) empowers Blopress API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Blopress JDMF during the approval evaluation for pharmaceutical products. At the time of Blopress JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Blopress suppliers with JDMF on PharmaCompass.

Blopress KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Blopress Drug Master File in Korea (Blopress KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Blopress. The MFDS reviews the Blopress KDMF as part of the drug registration process and uses the information provided in the Blopress KDMF to evaluate the safety and efficacy of the drug.

After submitting a Blopress KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Blopress API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Blopress suppliers with KDMF on PharmaCompass.

Blopress CEP

A Blopress CEP of the European Pharmacopoeia monograph is often referred to as a Blopress Certificate of Suitability (COS). The purpose of a Blopress CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Blopress EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Blopress to their clients by showing that a Blopress CEP has been issued for it. The manufacturer submits a Blopress CEP (COS) as part of the market authorization procedure, and it takes on the role of a Blopress CEP holder for the record. Additionally, the data presented in the Blopress CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Blopress DMF.

A Blopress CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Blopress CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Blopress suppliers with CEP (COS) on PharmaCompass.

Blopress WC

A Blopress written confirmation (Blopress WC) is an official document issued by a regulatory agency to a Blopress manufacturer, verifying that the manufacturing facility of a Blopress active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Blopress APIs or Blopress finished pharmaceutical products to another nation, regulatory agencies frequently require a Blopress WC (written confirmation) as part of the regulatory process.

click here to find a list of Blopress suppliers with Written Confirmation (WC) on PharmaCompass.

Blopress NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Blopress as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Blopress API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Blopress as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Blopress and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Blopress NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Blopress suppliers with NDC on PharmaCompass.

Blopress GMP

Blopress Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Blopress GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Blopress GMP manufacturer or Blopress GMP API supplier for your needs.

Blopress CoA

A Blopress CoA (Certificate of Analysis) is a formal document that attests to Blopress's compliance with Blopress specifications and serves as a tool for batch-level quality control.

Blopress CoA mostly includes findings from lab analyses of a specific batch. For each Blopress CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Blopress may be tested according to a variety of international standards, such as European Pharmacopoeia (Blopress EP), Blopress JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Blopress USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty